Arcutis Biotherapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Arcutis Biotherapeutics Inc Unternehmen

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Arcutis Biotherapeutics Inc Informationen



BörsenkürzelARQT

Name des UnternehmensArcutis Biotherapeutics Inc

IPO-datumJan 31, 2020

CEOMr. Todd Franklin Watanabe

Anzahl der mitarbeiter342

WertpapierartOrdinary Share

GeschäftsjahresendeJan 31

Addresse3027 Townsgate Road

StadtWESTLAKE VILLAGE

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl91361

Telefon18054185006

Websitehttps://arcutis.com/

BörsenkürzelARQT

IPO-datumJan 31, 2020

CEOMr. Todd Franklin Watanabe

Führungskräfte von Arcutis Biotherapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

603.10K

-1.88%

Dr. Howard G. Welgus, M.D.

Independent Director

89.74K

-10.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

64.93K

-0.14%

Mr. Patrick J. Heron

Independent Chairman of the Board

42.51K

+60.82%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

28.59K

-20.14%

Ms. Sue-Jean Lin

Independent Director

26.73K

+39.78%

Ms. Neha Krishnamohan

Independent Director

23.36K

+48.32%

Ms. Terrie J. Curran

Independent Director

--

Ms. Halley E. Gilbert, J.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

603.10K

-1.88%

Dr. Howard G. Welgus, M.D.

Independent Director

89.74K

-10.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

64.93K

-0.14%

Mr. Patrick J. Heron

Independent Chairman of the Board

42.51K

+60.82%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

28.59K

-20.14%

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Oct 11

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Jennison Associates LLC

10.00%

Suvretta Capital Management, LLC

9.42%

Rubric Capital Management LP

8.78%

Frazier Life Sciences Management, L.P.

8.06%

BlackRock Institutional Trust Company, N.A.

6.21%

Andere

57.53%

Aktionäre

Anteil

Jennison Associates LLC

10.00%

Suvretta Capital Management, LLC

9.42%

Rubric Capital Management LP

8.78%

Frazier Life Sciences Management, L.P.

8.06%

BlackRock Institutional Trust Company, N.A.

6.21%

Andere

57.53%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor/Hedge Fund

33.31%

Investment Advisor

30.23%

Hedge Fund

29.84%

Private Equity

8.06%

Research Firm

5.80%

Individual Investor

1.99%

Venture Capital

1.76%

Bank and Trust

0.40%

Pension Fund

0.28%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

476

134.55M

109.88%

-12.09M

2025Q2

481

131.17M

109.40%

-22.25M

2025Q1

487

132.87M

111.51%

-24.00M

2024Q4

453

136.04M

114.96%

-23.73M

2024Q3

433

136.12M

116.66%

-19.10M

2024Q2

416

134.94M

116.78%

-20.37M

2024Q1

392

131.83M

115.81%

+2.26M

2023Q4

366

104.30M

108.66%

+5.22M

2023Q3

364

79.57M

131.78%

-15.32M

2023Q2

359

84.02M

139.44%

-6.66M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Jennison Associates LLC

12.25M

10.22%

+1.14M

+10.30%

Sep 30, 2025

Suvretta Capital Management, LLC

11.54M

9.62%

+112.60K

+0.99%

Jun 30, 2025

Rubric Capital Management LP

10.75M

8.96%

-217.22K

-1.98%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

9.87M

8.24%

+7.00

+0.00%

Aug 18, 2025

BlackRock Institutional Trust Company, N.A.

7.61M

6.35%

-296.14K

-3.75%

Jun 30, 2025

The Vanguard Group, Inc.

7.02M

5.86%

+231.02K

+3.40%

Jun 30, 2025

Polar Capital LLP

5.01M

4.18%

-1.70M

-25.35%

Jun 30, 2025

State Street Investment Management (US)

4.53M

3.78%

+52.73K

+1.18%

Jun 30, 2025

Gilder Gagnon Howe & Co. LLC

4.16M

3.47%

+59.71K

+1.46%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.75M

3.13%

+672.66K

+21.86%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Simplify Health Care ETF

4.74%

Invesco Dorsey Wright Healthcare Momentum ETF

1.44%

Global X Guru Index ETF

1.37%

Virtus LifeSci Biotech Clinical Trials ETF

1.01%

SPDR S&P Biotech ETF

0.72%

First Trust Small Cap Growth AlphaDEX Fund

0.44%

Federated Hermes MDT Small Cap Core ETF

0.41%

Direxion Daily S&P Biotech Bull 3X Shares

0.38%

Inspire Small/Mid Cap ESG ETF

0.26%

ProShares Ultra Nasdaq Biotechnology

0.23%

Simplify Health Care ETF

Anteil4.74%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil1.44%

Global X Guru Index ETF

Anteil1.37%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.01%

SPDR S&P Biotech ETF

Anteil0.72%

First Trust Small Cap Growth AlphaDEX Fund

Anteil0.44%

Federated Hermes MDT Small Cap Core ETF

Anteil0.41%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.38%

Inspire Small/Mid Cap ESG ETF

Anteil0.26%

ProShares Ultra Nasdaq Biotechnology

Anteil0.23%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten